Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 26, 2021
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Journal: Molecular cancer therapeutics
Published: March 01, 2021
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Journal: Cancer immunology research
Published: January 13, 2021
A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 Ligands.
Journal: SLAS discovery : advancing life sciences R & D
Published: July 28, 2020
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072.
Journal: Clinical pharmacology and therapeutics
Published: March 11, 2020
Antibody prodrugs for cancer.
Journal: Expert opinion on biological therapy
Published: November 30, 2019
In vivo imaging of protease activity by Probody therapeutic activation.
Journal: Biochimie
Published: September 29, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 06, 2015
Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 22, 2014
Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.
Journal: Science translational medicine
Published: March 29, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026